amiodarone has been researched along with Atrial Flutter in 199 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Atrial Flutter: Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo." | 9.69 | Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial. ( Bigot, G; Blomström-Lundqvist, C; Hohnloser, SH; McKindley, DS; Naccarelli, GV; Wieloch, M, 2023) |
| "Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL)." | 9.51 | Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial. ( Bai, R; Lin, JL; Ma, C; Nam, GB; Stewart, J; Sun, Y; Wieloch, M; Zhu, J, 2022) |
| "Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties." | 9.15 | Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011) |
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 9.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I) or a destructive process (AIT II)." | 9.13 | The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Boi, F; Cocco, MC; Loy, M; Mariotti, S; Piga, M; Serra, A, 2008) |
| "There is no published randomized study comparing amiodarone therapy and radiofrequency catheter ablation (RFA) after only 1 episode of symptomatic atrial flutter (AFL)." | 9.12 | Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. ( Abdellaoui, L; Barthélemy, JC; Bonijoly, S; Da Costa, A; Defaye, P; Denis, L; Faure, E; Gonthier, R; Gouttard, T; Isaaz, K; Kruszynski, G; Lamaison, D; Messier, M; Pages, JM; Roche, F; Romeyer-Bouchard, C; Thévenin, J, 2006) |
| "The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR)." | 9.12 | Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. ( Chaveles, JI; Dagadaki, OK; Kafkas, NV; Kelesidis, KM; Mertzanos, GA; Papageorgiou, KI; Patsilinakos, SP, 2007) |
| "To investigate whether oral amiodarone administered before surgery for a short period in high dose would reduce the incidence of postoperative atrial fibrillation or atrial flutter and reduces the length of hospital stay." | 9.12 | High dose of amiodarone in a short-term period reduces the incidence of postoperative atrial fibrillation and atrial flutter. ( Alcalde, RV; Bodanese, LC; Castro, I; Feier, F; Goldani, MA; Guaragna, JC; Noer, R; Petracco, JB; Sussenbach, E, 2006) |
| "Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects." | 9.12 | Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. ( Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN, 2007) |
| "A prospective, randomized controlled trial of new-onset atrial fibrillation was conducted to compare the efficacy and safety of sotalol and amiodarone (active treatment) with rate control by digoxin alone for successful reversion to sinus rhythm at 48 hours." | 9.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "This study compared the efficacy and safety of intravenous dofetilide with amiodarone and placebo in converting atrial fibrillation or flutter to sinus rhythm." | 9.09 | Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. ( Alboni, P; Bianconi, L; Castro, A; Dinelli, M; Pappalardo, A; Richiardi, E; Santini, M, 2000) |
| " A randomized, open-label, digoxin-controlled study was undertaken to observe the efficacy and safety of the dosing regimen of amiodarone in treating recent-onset, persistent, atrial fibrillation and flutter with ventricular rates above 130 beats." | 9.08 | Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ( Chang, MS; Chen, CY; Chiang, HT; Hou, ZY; Lin, SL; Tu, MS; Woosley, RL, 1995) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 9.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "The primary objective was to evaluate the efficacy of propafenone compared with amiodarone in the reversion of atrial fibrillation or flutter." | 9.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of all-cause mortality regardless of concomitant heart failure." | 8.98 | Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. ( Feinberg, J; Gluud, C; Jakobsen, JC; Nielsen, EE; Safi, S; Sethi, NJ, 2018) |
| "Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter." | 8.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. ( Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report on the clinical effectiveness and cost-effectiveness of dronedarone for the treatment of atrial fibrillation (AF) or atrial flutter based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process." | 8.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter. ( Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N, 2010) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of dronedarone for the treatment of atrial fibrillation." | 8.84 | Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. ( Dale, KM; White, CM, 2007) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 8.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "We report a case of nonimmune hydrops fetalis caused by atrial flutter, which was successfully treated by intraperitoneal and intra-amniotic injections of amiodarone." | 7.83 | Successful treatment of atrial flutter by repeated intraperitoneal and intra-amniotic injections of amiodarone in a fetus with hydrops. ( Hsieh, CT; Lin, PH; Tsai, HD; Wu, HH, 2016) |
| "The ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/flutter (AF/AFL)." | 7.80 | Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. ( Jhaveri, M; Kim, MH; Koren, A; Lin, J, 2014) |
| "Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF)." | 7.79 | Efficacy and tolerability of dronedarone for patients with atrial fibrillation. ( Goldberger, JJ; Teme, T, 2013) |
| "Patients with persistent or paroxysmal atrial fibrillation and at least 1 risk factor for cardiovascular hospitalization were randomized to receive dronedarone (400 mg BID) or double-blind matching placebo and followed up for a minimum of 1 year to a common termination at 30 months." | 7.75 | Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "Ibutilide and amiodarone are used for the pharmacological conversion of atrial fibrillation (AF) or flutter (AFl), but their efficacy is rather moderate." | 7.73 | Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm. ( Dilaveris, P; Gialafos, E; Giannopoulos, G; Stefanadis, C; Synetos, A, 2005) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 7.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "Amiodarone may still be safely prescribed for Chinese patients who have baseline liver dysfunction." | 7.73 | Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. ( Chan, WW; Fung, JW; Ho, SS; Hui, HH; Kum, LC; Sanderson, JE; Wong, GW; Yu, CM, 2006) |
| "Amiodarone/Silymarin Treatment for Sustained Atrial Flutter." | 7.72 | Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs. ( Besch, H; Vereckei, A; Zipes, DP, 2003) |
| "Fetuses with incessant tachycardia and either hydrops fetalis (n=24) or ventricular dysfunction (n=2) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followed by daily maintenance therapy for <1 to 15 weeks." | 7.72 | Amiodarone therapy for drug-refractory fetal tachycardia. ( Cuneo, BF; Deal, BJ; Feinkind, L; Gotteiner, NL; Hussey, M; McGregor, SN; Meijboom, EJ; Michon, MM; Oudijk, MA; Parilla, BV; Strasburger, JF, 2004) |
| "Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not." | 7.72 | Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004) |
| "The study consisted of 83 patients with isthmus-dependent atrial flutter: 52 were taking amiodarone at the time of RFA (group 1) and 31 were in a drug-free state (group 2)." | 7.72 | Value of entrainment mapping in determining the isthmus-dependent nature of atrial flutter in the presence of amiodarone. ( Blanc, JJ; Fatemi, M; Mansourati, J; Rosu, R, 2004) |
| "EG was prospectively determined by introducing a premature stimulus and analyzing the response pattern during typical atrial flutter in 30 patients without antiarrhythmic drugs and in 20 patients under chronic oral amiodarone therapy." | 7.72 | Effect of chronic amiodarone therapy on excitable gap during typical human atrial flutter. ( Maury, P; Zimmermann, M, 2004) |
| "To evaluate whether ibutilide can convert atrial fibrillation or flutter in patients in whom amiodarone has failed." | 7.71 | Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. ( Heidland, UE; Heintzen, MP; Hennersdorf, MG; Perings, C; Perings, SM; Strauer, BE; Zühlke, C, 2002) |
| "The study included 70 patients who were treated with long-term oral amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or flutter (13 of 70, 19%)." | 7.71 | Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. ( Chatterjee, K; Cheng, J; Glatter, K; Kayser, S; Modin, G; Scheinman, MM; Yang, Y, 2001) |
| "The efficacy and safety of amiodarone in the management of atrial fibrillation (AF) or flutter in 108 Japanese patients with heart failure was retrospectively examined." | 7.71 | Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. ( Hagiwara, N; Hosaka, F; Imai, T; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Sugiura, R; Suzuki, T; Wakaumi, M; Yamada, Y, 2002) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 7.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "Among 92 consecutive patients with typical atrial flutter who underwent isthmus ablation 28 patients had atrial flutter without a history of previous atrial fibrillation (group I), 10 patients had atrial flutter following the initiation of amiodarone therapy for paroxysmal atrial fibrillation (group II) and 54 patients had atrial flutter and atrial fibrillation (group III)." | 7.70 | Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. ( Dorwarth, U; Gerth, A; Hoffmann, E; Reithmann, C; Remp, T; Spitzlberger, G; Steinbeck, G, 2000) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 7.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%." | 7.69 | Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996) |
| "Amiodarone is effective for long-term maintenance of sinus rhythm after electrical cardioversion of refractory atrial fibrillation or flutter." | 7.69 | Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. ( Crijns, HJ; de Kam, PJ; Gosselink, AT; Lie, KI; Tieleman, RG; van den Berg, MP; van Gelder, IC; van Gilst, WH, 1997) |
| "We report a case of amiodarone-induced thyrotoxicosis, diagnosed with a systematic laboratory investigation in a 64-year-old patient, for haematuria." | 7.69 | [Amiodarone-induced thyrotoxicosis cured by thyroidectomy]. ( Guerin-Robardey, AM; Le Cosquer, P; Ossart, M, 1996) |
| "Amiodarone resulted in a rapid ventricular response to atrial flutter in an infant with Wolff-Parkinson-White syndrome." | 7.68 | Acceleration of the ventricular response to atrial flutter by amiodarone in an infant with Wolff-Parkinson-White syndrome. ( Baxendall, M; Benetar, A; Till, JA, 1993) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 7.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "To compare the efficacy and safety of intravenous (IV) amiodarone and procainamide for the treatment of atrial tachyarrhythmias (AT) in the critically ill." | 7.68 | Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. ( Chapman, MJ; Cunningham, DN; Moran, JL; O'Fathartaigh, MS; Peisach, AR, 1993) |
| "The safety and efficacy of short intravenous therapy with amiodarone were evaluated in 44 patients (24 males, 20 females), aged 21-84 years, with supraventricular tachyarrhythmias newly arisen in less than 24 hours." | 7.68 | Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. ( Burzio, P; Latini, R; Marchisio, U; Veglio, F; Vietti-Ramus, G, 1992) |
| "To shorten the delay in the onset of antiarrhythmic effect when using amiodarone for the conversion of refractory atrial tachyarrhythmias to sinus rhythm, 19 patients were given oral amiodarone according to a high-dose loading protocol." | 7.68 | Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. ( Mostow, ND; Noon, D; Rakita, L; Vrobel, TR, 1990) |
| "Oral amiodarone was administered to 30 children (aged one week to 14 years) for treatment of resistant or life threatening tachycardias." | 7.67 | Intravenous and oral amiodarone for arrhythmias in children. ( Bucknall, CA; Curry, PV; Holt, DW; Keeton, BR; Sutherland, GR; Tynan, MJ, 1986) |
| "A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias." | 7.67 | Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. ( Clarke, B; Honey, M; Ward, DE, 1985) |
| "We tested the efficacy of intravenous amiodarone (5 mg/kg) in slowing ventricular response and/or restoring sinus rhythm in 26 patients with paroxysmal or new atrial fibrillation with fast ventricular response." | 7.67 | Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. ( Agmon, J; Arditti, A; Buimovici, B; Lewin, RF; Sclarovsky, S; Strasberg, B, 1985) |
| "Amiodarone was administered to 121 patients (82 males, 39 females; average age 59 years) with refractory atrial tachyarrhythmias." | 7.66 | Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. ( Graboys, TB; Lown, B; Podrid, PJ, 1983) |
| "Twenty-four consecutive episodes of atrial flutter in 20 patients were treated with overdrive atrial pacing after a pre-treatment with oral Amiodarone." | 7.66 | [High-frequency electrostimulation of the atrium in therapy of atrial flutter in patients pre-treated with amiodarone]. ( Buchberger, R; Candelpergher, G; Cernetti, C; Simoncello, P; Suzzi, G, 1982) |
| "Oral amiodarone has been used to treat 21 patients with various supraventricular arrhythmias; 13 had Wolff-Parkinson-White syndrome, which was complicated by atrial fibrillation and re-entry atrioventricular tachycardia in four, and re-entry tachycardia alone in the other nine." | 7.66 | Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. ( Krikler, DM; Rowland, E, 1980) |
| "Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function." | 7.11 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. ( Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022) |
| "The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events." | 7.11 | Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. ( Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J, 2022) |
| " The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age." | 7.11 | Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter. ( Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP, 2022) |
| "Dronedarone is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added." | 6.50 | The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS. ( Kowey, PR; Naccarelli, GV, 2014) |
| "Amiodarone was continued for 45 days; there was no recurrence of atrial flutter." | 6.44 | Successful treatment of atrial flutter with amiodarone in a premature neonate. Case report and literature review. ( Bauersfeld, U; Knirsch, W; Kretschmar, O; Uhlemann, F; Vogel, M, 2007) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 6.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo." | 5.69 | Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial. ( Bigot, G; Blomström-Lundqvist, C; Hohnloser, SH; McKindley, DS; Naccarelli, GV; Wieloch, M, 2023) |
| "Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL)." | 5.51 | Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial. ( Bai, R; Lin, JL; Ma, C; Nam, GB; Stewart, J; Sun, Y; Wieloch, M; Zhu, J, 2022) |
| "Perinatal atrial flutter is a serious arrhythmia." | 5.42 | [Repeated electrical cardioversions and amiodarone for recurrent neonatal atrial flutter]. ( Crochelet, AS; Jacquemart, C; Massin, M, 2015) |
| "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation." | 5.36 | Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. ( Duray, GZ; Hohnloser, SH; Schmitt, J, 2010) |
| "1/1 atrial flutter is a regularly described complication of class I anti-arrhythmics." | 5.33 | [1/1 nodo-ventricular conduction atrial flutter with amiodarone]. ( Diebold, B; Le Heuzey, JY; Paziaud, O; Perdrix-Andujar, L; Ricard, G, 2005) |
| "During follow-up a recurrence rate of 33% was observed in Group 1 (6 recurrences in 18 patients; p < 0." | 5.32 | Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter. ( Elvas, L; Providência, L; Ventura, M, 2004) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 5.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "Rapid atrial flutter was seen on ultrasound in a fetus with severe hydrops at 27 weeks' gestation." | 5.29 | Amiodarone given by three routes to terminate fetal atrial flutter associated with severe hydrops. ( Bennett, PR; Fisk, NM; Flack, NJ; Vaughan, J; Zosmer, N, 1993) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "amiodarone was administered (repeated boluses of 3 mg/kg in 3 min, or 30 min-infusions of 5 to 7." | 5.27 | Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. ( Faniel, R; Schoenfeld, P, 1983) |
| "Amiodarone i." | 5.26 | [Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias]. ( Bianchi, C; Bonifazi, C; Coppetti, S; Distante, S; Ferrari, O; Ricevuti, A; Rinaldo, R; Rizzi, M; Tavecchi, L; Zampaglione, G; Ziletti, G, 1981) |
| "Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties." | 5.15 | Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2011) |
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 5.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I) or a destructive process (AIT II)." | 5.13 | The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Boi, F; Cocco, MC; Loy, M; Mariotti, S; Piga, M; Serra, A, 2008) |
| "A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation." | 5.12 | Circumferential pulmonary-vein ablation for chronic atrial fibrillation. ( Agricola, E; Augello, G; Bates, ER; Bogun, F; Chugh, A; Good, E; Lehmann, MH; Morady, F; Oral, H; Pappone, C; Pelosi, F; Sala, S; Santinelli, V; Vicedomini, G, 2006) |
| "There is no published randomized study comparing amiodarone therapy and radiofrequency catheter ablation (RFA) after only 1 episode of symptomatic atrial flutter (AFL)." | 5.12 | Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. ( Abdellaoui, L; Barthélemy, JC; Bonijoly, S; Da Costa, A; Defaye, P; Denis, L; Faure, E; Gonthier, R; Gouttard, T; Isaaz, K; Kruszynski, G; Lamaison, D; Messier, M; Pages, JM; Roche, F; Romeyer-Bouchard, C; Thévenin, J, 2006) |
| "The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR)." | 5.12 | Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. ( Chaveles, JI; Dagadaki, OK; Kafkas, NV; Kelesidis, KM; Mertzanos, GA; Papageorgiou, KI; Patsilinakos, SP, 2007) |
| "To investigate whether oral amiodarone administered before surgery for a short period in high dose would reduce the incidence of postoperative atrial fibrillation or atrial flutter and reduces the length of hospital stay." | 5.12 | High dose of amiodarone in a short-term period reduces the incidence of postoperative atrial fibrillation and atrial flutter. ( Alcalde, RV; Bodanese, LC; Castro, I; Feier, F; Goldani, MA; Guaragna, JC; Noer, R; Petracco, JB; Sussenbach, E, 2006) |
| "Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects." | 5.12 | Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. ( Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN, 2007) |
| "A prospective, randomized controlled trial of new-onset atrial fibrillation was conducted to compare the efficacy and safety of sotalol and amiodarone (active treatment) with rate control by digoxin alone for successful reversion to sinus rhythm at 48 hours." | 5.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "This study compared the efficacy and safety of intravenous dofetilide with amiodarone and placebo in converting atrial fibrillation or flutter to sinus rhythm." | 5.09 | Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. ( Alboni, P; Bianconi, L; Castro, A; Dinelli, M; Pappalardo, A; Richiardi, E; Santini, M, 2000) |
| " A randomized, open-label, digoxin-controlled study was undertaken to observe the efficacy and safety of the dosing regimen of amiodarone in treating recent-onset, persistent, atrial fibrillation and flutter with ventricular rates above 130 beats." | 5.08 | Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ( Chang, MS; Chen, CY; Chiang, HT; Hou, ZY; Lin, SL; Tu, MS; Woosley, RL, 1995) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 5.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "The primary objective was to evaluate the efficacy of propafenone compared with amiodarone in the reversion of atrial fibrillation or flutter." | 5.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| " We set out to compare the relative efficacy of amiodarone and digoxin in the management of atrial fibrillation and flutter in the early postoperative period." | 5.07 | A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery. ( Cochrane, AD; Davis, BB; Marasco, S; McConaghy, L; Rosenfeldt, FL; Salamonsen, R; Siddins, M, 1994) |
| "During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of all-cause mortality regardless of concomitant heart failure." | 4.98 | Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. ( Feinberg, J; Gluud, C; Jakobsen, JC; Nielsen, EE; Safi, S; Sethi, NJ, 2018) |
| "Reports published with the following search terms were searched:, thyroid, hypothyroidism, hyperthyroidism, subclinical hyperthyroidism, subclinical hypothyroidism, levothyroxine, triiodothyronine, antithyroid drugs, radioiodine, deiodinases, clinical symptoms, heart rate, HF, systolic function, diastolic function, systemic vascular resistance, endothelial function, amiodarone and atrial fibrillation." | 4.88 | Mechanisms in endocrinology: Heart failure and thyroid dysfunction. ( Biondi, B, 2012) |
| "Dronedarone is developed for treatment of atrial fibrillation (AF) or flutter (AFL)." | 4.86 | Efficacy and safety of dronedarone: a review of randomized trials. ( Christiansen, CB; Køber, L; Torp-Pedersen, C, 2010) |
| "Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter." | 4.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. ( Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D, 2010) |
| "Approved in July 2009, dronedarone is a new antiarrhythmic agent indicated to reduce the risk of hospitalization for cardiac events in patients with paroxysmal or persistent atrial fibrillation or atrial flutter." | 4.86 | Dronedarone: an alternative to amiodarone? ( Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report on the clinical effectiveness and cost-effectiveness of dronedarone for the treatment of atrial fibrillation (AF) or atrial flutter based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process." | 4.86 | Dronedarone for the treatment of atrial fibrillation and atrial flutter. ( Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N, 2010) |
| "Amiodarone is the most effective antiarrhythmic drug for maintaining sinus rhythm for patients with atrial fibrillation." | 4.85 | Dronedarone. ( Kowey, PR; Patel, C; Yan, GX, 2009) |
| "To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of dronedarone for the treatment of atrial fibrillation." | 4.84 | Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. ( Dale, KM; White, CM, 2007) |
| " Trials that assessed whether amiodarone prophylaxis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were not specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality." | 4.82 | Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. ( Aasbo, JD; Kim, MH; Krishnan, K; Lawrence, AT; Trohman, RG, 2005) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 4.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "We report a case of nonimmune hydrops fetalis caused by atrial flutter, which was successfully treated by intraperitoneal and intra-amniotic injections of amiodarone." | 3.83 | Successful treatment of atrial flutter by repeated intraperitoneal and intra-amniotic injections of amiodarone in a fetus with hydrops. ( Hsieh, CT; Lin, PH; Tsai, HD; Wu, HH, 2016) |
| "The ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/flutter (AF/AFL)." | 3.80 | Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. ( Jhaveri, M; Kim, MH; Koren, A; Lin, J, 2014) |
| "Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months." | 3.80 | Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| " She was recently diagnosed with refractory atrial flutter and was prescribed amiodarone." | 3.79 | Ataxia: a diagnostic perplexity and management dilemma. ( Chaubey, VK; Chhabra, L; Kapila, A, 2013) |
| "Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF)." | 3.79 | Efficacy and tolerability of dronedarone for patients with atrial fibrillation. ( Goldberger, JJ; Teme, T, 2013) |
| "The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0." | 3.76 | Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. ( Johnston, SS; Lin, J; Naccarelli, GV; Patel, PP; Schulman, KL, 2010) |
| "Patients with persistent or paroxysmal atrial fibrillation and at least 1 risk factor for cardiovascular hospitalization were randomized to receive dronedarone (400 mg BID) or double-blind matching placebo and followed up for a minimum of 1 year to a common termination at 30 months." | 3.75 | Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| " The ATHENA study showed that dronedarone reduced the incidence of the composite outcome of cardiovascular hospitalisation or death, in patients with atrial fibrillation or flutter, 29% of whom had a history of heart failure, compared with placebo." | 3.74 | Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. ( Clark, AL; Cleland, JG; Coletta, AP; Cullington, D, 2008) |
| "Ibutilide and amiodarone are used for the pharmacological conversion of atrial fibrillation (AF) or flutter (AFl), but their efficacy is rather moderate." | 3.73 | Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm. ( Dilaveris, P; Gialafos, E; Giannopoulos, G; Stefanadis, C; Synetos, A, 2005) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 3.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "Amiodarone may still be safely prescribed for Chinese patients who have baseline liver dysfunction." | 3.73 | Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. ( Chan, WW; Fung, JW; Ho, SS; Hui, HH; Kum, LC; Sanderson, JE; Wong, GW; Yu, CM, 2006) |
| "Amiodarone/Silymarin Treatment for Sustained Atrial Flutter." | 3.72 | Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs. ( Besch, H; Vereckei, A; Zipes, DP, 2003) |
| "Fetuses with incessant tachycardia and either hydrops fetalis (n=24) or ventricular dysfunction (n=2) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followed by daily maintenance therapy for <1 to 15 weeks." | 3.72 | Amiodarone therapy for drug-refractory fetal tachycardia. ( Cuneo, BF; Deal, BJ; Feinkind, L; Gotteiner, NL; Hussey, M; McGregor, SN; Meijboom, EJ; Michon, MM; Oudijk, MA; Parilla, BV; Strasburger, JF, 2004) |
| "Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not." | 3.72 | Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004) |
| "The study consisted of 83 patients with isthmus-dependent atrial flutter: 52 were taking amiodarone at the time of RFA (group 1) and 31 were in a drug-free state (group 2)." | 3.72 | Value of entrainment mapping in determining the isthmus-dependent nature of atrial flutter in the presence of amiodarone. ( Blanc, JJ; Fatemi, M; Mansourati, J; Rosu, R, 2004) |
| "EG was prospectively determined by introducing a premature stimulus and analyzing the response pattern during typical atrial flutter in 30 patients without antiarrhythmic drugs and in 20 patients under chronic oral amiodarone therapy." | 3.72 | Effect of chronic amiodarone therapy on excitable gap during typical human atrial flutter. ( Maury, P; Zimmermann, M, 2004) |
| "To evaluate whether ibutilide can convert atrial fibrillation or flutter in patients in whom amiodarone has failed." | 3.71 | Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. ( Heidland, UE; Heintzen, MP; Hennersdorf, MG; Perings, C; Perings, SM; Strauer, BE; Zühlke, C, 2002) |
| "The study included 70 patients who were treated with long-term oral amiodarone and were referred for elective cardioversion of atrial fibrillation (57 of 70, 81%) or flutter (13 of 70, 19%)." | 3.71 | Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. ( Chatterjee, K; Cheng, J; Glatter, K; Kayser, S; Modin, G; Scheinman, MM; Yang, Y, 2001) |
| "The efficacy and safety of amiodarone in the management of atrial fibrillation (AF) or flutter in 108 Japanese patients with heart failure was retrospectively examined." | 3.71 | Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. ( Hagiwara, N; Hosaka, F; Imai, T; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Sugiura, R; Suzuki, T; Wakaumi, M; Yamada, Y, 2002) |
| "Ibutilide, with a unique increase in atrial refractoriness, was more effective in conversion of atrial flutter than were propafenone and amiodarone." | 3.70 | Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. ( Chang, MS; Chen, SA; Chen, YJ; Feng, AN; Tai, CT; Yu, WC, 1998) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 3.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "Among 92 consecutive patients with typical atrial flutter who underwent isthmus ablation 28 patients had atrial flutter without a history of previous atrial fibrillation (group I), 10 patients had atrial flutter following the initiation of amiodarone therapy for paroxysmal atrial fibrillation (group II) and 54 patients had atrial flutter and atrial fibrillation (group III)." | 3.70 | Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. ( Dorwarth, U; Gerth, A; Hoffmann, E; Reithmann, C; Remp, T; Spitzlberger, G; Steinbeck, G, 2000) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 3.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%." | 3.69 | Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996) |
| "A 66-year-old man suffering from atrial flutter developed cutaneous blue-gray pigmentation while receiving 600 mg of amiodarone daily for 15 months." | 3.69 | Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. ( Frangides, C; Goudevenos, J; Kounis, NG; Papadaki, PJ; Zavras, GM, 1996) |
| "Amiodarone is effective for long-term maintenance of sinus rhythm after electrical cardioversion of refractory atrial fibrillation or flutter." | 3.69 | Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. ( Crijns, HJ; de Kam, PJ; Gosselink, AT; Lie, KI; Tieleman, RG; van den Berg, MP; van Gelder, IC; van Gilst, WH, 1997) |
| "We report a case of amiodarone-induced thyrotoxicosis, diagnosed with a systematic laboratory investigation in a 64-year-old patient, for haematuria." | 3.69 | [Amiodarone-induced thyrotoxicosis cured by thyroidectomy]. ( Guerin-Robardey, AM; Le Cosquer, P; Ossart, M, 1996) |
| "Amiodarone resulted in a rapid ventricular response to atrial flutter in an infant with Wolff-Parkinson-White syndrome." | 3.68 | Acceleration of the ventricular response to atrial flutter by amiodarone in an infant with Wolff-Parkinson-White syndrome. ( Baxendall, M; Benetar, A; Till, JA, 1993) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 3.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "To compare the efficacy and safety of intravenous (IV) amiodarone and procainamide for the treatment of atrial tachyarrhythmias (AT) in the critically ill." | 3.68 | Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. ( Chapman, MJ; Cunningham, DN; Moran, JL; O'Fathartaigh, MS; Peisach, AR, 1993) |
| "The safety and efficacy of short intravenous therapy with amiodarone were evaluated in 44 patients (24 males, 20 females), aged 21-84 years, with supraventricular tachyarrhythmias newly arisen in less than 24 hours." | 3.68 | Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. ( Burzio, P; Latini, R; Marchisio, U; Veglio, F; Vietti-Ramus, G, 1992) |
| "To shorten the delay in the onset of antiarrhythmic effect when using amiodarone for the conversion of refractory atrial tachyarrhythmias to sinus rhythm, 19 patients were given oral amiodarone according to a high-dose loading protocol." | 3.68 | Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. ( Mostow, ND; Noon, D; Rakita, L; Vrobel, TR, 1990) |
| "A patient with sick sinus syndrome and resistant paroxysmal atrial flutter was treated with amiodarone and implanted with a Medtronic 7005 DDD pacemaker." | 3.67 | Noninvasive conversion of atrial flutter using a multiprogrammable DDD pulse generator. ( Castellanos, A; Luceri, RM; Myerburg, RJ; Thurer, RJ, 1986) |
| "Oral amiodarone was administered to 30 children (aged one week to 14 years) for treatment of resistant or life threatening tachycardias." | 3.67 | Intravenous and oral amiodarone for arrhythmias in children. ( Bucknall, CA; Curry, PV; Holt, DW; Keeton, BR; Sutherland, GR; Tynan, MJ, 1986) |
| "A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias." | 3.67 | Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. ( Clarke, B; Honey, M; Ward, DE, 1985) |
| "We tested the efficacy of intravenous amiodarone (5 mg/kg) in slowing ventricular response and/or restoring sinus rhythm in 26 patients with paroxysmal or new atrial fibrillation with fast ventricular response." | 3.67 | Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. ( Agmon, J; Arditti, A; Buimovici, B; Lewin, RF; Sclarovsky, S; Strasberg, B, 1985) |
| "Our use of amiodarone in 200 patients during an 8-year period confirms our previous experience which indicated that the drug was close to being the ideal antiarrhythmic agent in children's arrhythmias." | 3.66 | The use of amiodarone in children. ( Coumel, P; Do Ngoc, D; Lucet, V, 1983) |
| "Amiodarone was administered to 121 patients (82 males, 39 females; average age 59 years) with refractory atrial tachyarrhythmias." | 3.66 | Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. ( Graboys, TB; Lown, B; Podrid, PJ, 1983) |
| "Twenty-four consecutive episodes of atrial flutter in 20 patients were treated with overdrive atrial pacing after a pre-treatment with oral Amiodarone." | 3.66 | [High-frequency electrostimulation of the atrium in therapy of atrial flutter in patients pre-treated with amiodarone]. ( Buchberger, R; Candelpergher, G; Cernetti, C; Simoncello, P; Suzzi, G, 1982) |
| "Oral amiodarone has been used to treat 21 patients with various supraventricular arrhythmias; 13 had Wolff-Parkinson-White syndrome, which was complicated by atrial fibrillation and re-entry atrioventricular tachycardia in four, and re-entry tachycardia alone in the other nine." | 3.66 | Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. ( Krikler, DM; Rowland, E, 1980) |
| "Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function." | 3.11 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. ( Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022) |
| "The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events." | 3.11 | Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. ( Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J, 2022) |
| " The incidence of all treatment-emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation was comparable among males and females, and increased with increasing age." | 3.11 | Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter. ( Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP, 2022) |
| "AFL accounts for 30% of fetal tachyarrhythmias, 11% to 18% of neonatal tachyarrhythmias, and 8% of supraventricular tachyarrhythmias in children older than 1 year of age." | 2.82 | Atrial Flutter in Pediatric Patients. ( Drago, F; Tamborrino, PP, 2022) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Amiodarone was used for 212 patients (51." | 2.71 | Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2003) |
| "Amiodarone has been the only drug so far reported to give a combination of high efficacy and low frequency of serious side effects such as ventricular tachycardia and shock." | 2.69 | Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia? ( Møller, S; Nielsen, KD, 2000) |
| "Amiodarone is an extremely effective treatment for infants and children with tachyarrhythmias resistant to conventional treatment." | 2.65 | Amiodarone treatment of critical arrhythmias in children and young adults. ( Angell, LK; Garson, A; Gillette, PC; Hesslein, PS; Hittner, HM; Kaldis, LC; McVey, P; Porter, CJ, 1984) |
| "Dronedarone is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added." | 2.50 | The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS. ( Kowey, PR; Naccarelli, GV, 2014) |
| "Dronedarone is a multichannel blocker with electrophysiologic effects similar to amiodarone." | 2.46 | A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission. ( Banchs, JE; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, E; Samii, S; Wolbrette, DL, 2010) |
| "Amiodarone was continued for 45 days; there was no recurrence of atrial flutter." | 2.44 | Successful treatment of atrial flutter with amiodarone in a premature neonate. Case report and literature review. ( Bauersfeld, U; Knirsch, W; Kretschmar, O; Uhlemann, F; Vogel, M, 2007) |
| "Dronedarone is a noniodinated benzofuran derivative that has been developed to overcome the limiting iodine-associated adverse effects of the commonly used antiarrhythmic drug, amiodarone." | 2.43 | The novel antiarrhythmic drug dronedarone: comparison with amiodarone. ( Karle, CA; Kathofer, S; Thomas, D, 2005) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| "Cardiac arrhythmias are common in the perioperative period." | 2.41 | Postoperative arrhythmias and conduction disorders. ( Sloan, SB; Weitz, HH, 2001) |
| "Amiodarone is a structural analogue of thyroid hormone and some of its anti-arrhythmic properties and toxicity may be attributable to interactions with nuclear thyroid hormone receptors." | 2.41 | Amiodarone -- waxed and waned and waxed again. ( Doggrell, SA, 2001) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 2.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "Atrial flutter (AFL) is an uncommon arrhythmia in the pediatric population." | 1.56 | Atrial Flutter-Unique Arrhythmia in Neonatal Population, Presentation of 3 Cases. ( Kędziora, P; Stasiak, A, 2020) |
| "In all, 374 (53." | 1.42 | The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department. ( Clark, D; Cragg, A; Gray, A; Grubb, N; Hamilton, A, 2015) |
| "Perinatal atrial flutter is a serious arrhythmia." | 1.42 | [Repeated electrical cardioversions and amiodarone for recurrent neonatal atrial flutter]. ( Crochelet, AS; Jacquemart, C; Massin, M, 2015) |
| "Dronedarone is a novel class III antiarrhythmic drug with moderate efficacy in preventing atrial arrhythmias." | 1.39 | Usefulness of dronedarone in patients with atrial arrhythmias. ( Bollmann, A; Hindricks, G; Husser, D; John, S; Kornej, J; Löbe, S; Salmáš, J, 2013) |
| "Amiodarone was shown to be a significant statistical moderator (p < 0." | 1.37 | Atrial arrhythmias after lung and heart-lung transplant: effects on short-term mortality and the influence of amiodarone. ( Cordova, F; Criner, G; Gaughan, J; Isiadinso, I; Lim, S; Meshkov, AB; Sandhu, P, 2011) |
| "Dronedarone was used mostly in compliance with PI and risk evaluation and mitigation strategy in the studied population." | 1.37 | Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database. ( Dai, WS; Gao, S; Juhaeri, J; Koren, AT; Schiappacasse, HA, 2011) |
| "Amiodarone is an effective antiarrhythmic agent and represents the drug of choice in the treatment of severe arrhythmias, especially in the setting of ventricular dysfunction." | 1.36 | Incompatibility between intravenous amiodarone and heparin in an infant. ( Boriani, G; Bronzetti, G; D'Angelo, C; Mariucci, E; Picchio, FM, 2010) |
| "Amiodarone was given initially to the other 4 patients in whom adenosine caused only temporary conversion to the sinus rhythm." | 1.36 | Intravenous amiodarone used alone or in combination with digoxin for life-threatening supraventricular tachyarrhythmia in neonates and small infants. ( Aslan, Y; Celiker, A; Dilber, B; Dilber, E; Gedik, Y; Mutlu, M, 2010) |
| "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation." | 1.36 | Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. ( Duray, GZ; Hohnloser, SH; Schmitt, J, 2010) |
| "Atrial thrombosis is a relatively rare event in children." | 1.35 | Resolution of atrial thrombosis with heparin in a newborn with atrial flutter. ( Angelini, A; Boriani, G; Bronzetti, G; D'Angelo, C; Picchio, FM, 2009) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| "1/1 atrial flutter is a regularly described complication of class I anti-arrhythmics." | 1.33 | [1/1 nodo-ventricular conduction atrial flutter with amiodarone]. ( Diebold, B; Le Heuzey, JY; Paziaud, O; Perdrix-Andujar, L; Ricard, G, 2005) |
| "During follow-up a recurrence rate of 33% was observed in Group 1 (6 recurrences in 18 patients; p < 0." | 1.32 | Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter. ( Elvas, L; Providência, L; Ventura, M, 2004) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 1.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "Atrial tachyarrhythmias were induced by right atrial burst pacing." | 1.30 | Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system. ( Fries, R; Heisel, A; Jung, J; Ozbek, C; Schieffer, H; Sen, S; Stopp, M, 1997) |
| "Rapid atrial flutter was seen on ultrasound in a fetus with severe hydrops at 27 weeks' gestation." | 1.29 | Amiodarone given by three routes to terminate fetal atrial flutter associated with severe hydrops. ( Bennett, PR; Fisk, NM; Flack, NJ; Vaughan, J; Zosmer, N, 1993) |
| "Prevention of recurrence with oral amiodarone was effective in all cases but was responsible for secondary effects in 4 cases." | 1.29 | [Late supraventricular arrhythmia complicating Fontan or cavopulmonary type procedures. Apropos of 7 cases]. ( David, N; Foucault, JP; Iselin, M; Maragnès, P; Villain, E, 1996) |
| "When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "amiodarone was administered (repeated boluses of 3 mg/kg in 3 min, or 30 min-infusions of 5 to 7." | 1.27 | Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. ( Faniel, R; Schoenfeld, P, 1983) |
| "Amiodarone has been reported to be a remarkably safe and effective drug in the European and South American experience but American investigators have published conflicting data." | 1.27 | Safety and efficacy of amiodarone. The low-dose perspective. ( Friehling, TD; Kowey, PR; Marinchak, RA; Stohler, JL; Sulpizi, AM, 1988) |
| "Amiodarone was used for recurrent supraventricular tachycardia in four cases and frequent ventricular extra systoles complicating congenital QT prolongation in the remaining case." | 1.27 | Amiodarone-induced torsades de pointes. ( Brown, MA; Lubbe, WF; Norris, RM; Smith, WM, 1986) |
| "When amiodarone was stopped in nine patients, the changes in QTc, T4 and rT3 regressed toward normal and arrhythmia recurred in eight 2-20 weeks (mean 7." | 1.26 | Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ( Hendrickson, JA; Hershman, J; Melmed, S; Nademanee, K; Reed, AW; Singh, BN, 1982) |
| "Amiodarone i." | 1.26 | [Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias]. ( Bianchi, C; Bonifazi, C; Coppetti, S; Distante, S; Ferrari, O; Ricevuti, A; Rinaldo, R; Rizzi, M; Tavecchi, L; Zampaglione, G; Ziletti, G, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (19.10) | 18.7374 |
| 1990's | 44 (22.11) | 18.2507 |
| 2000's | 72 (36.18) | 29.6817 |
| 2010's | 35 (17.59) | 24.3611 |
| 2020's | 10 (5.03) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, YH | 1 |
| Ma, CS | 1 |
| Wu, SL | 1 |
| Vamos, M | 1 |
| Oldgren, J | 1 |
| Nam, GB | 2 |
| Lip, GYH | 1 |
| Calkins, H | 1 |
| Zhu, J | 4 |
| Ueng, KC | 1 |
| Ludwigs, U | 2 |
| Wieloch, M | 4 |
| Stewart, J | 5 |
| Hohnloser, SH | 9 |
| Thind, M | 2 |
| Zareba, W | 1 |
| Atar, D | 2 |
| Crijns, HJGM | 1 |
| Pak, HN | 1 |
| Reiffel, J | 1 |
| Kowey, P | 1 |
| McKindley, DS | 2 |
| Reiffel, JA | 1 |
| Naccarelli, GV | 7 |
| Kowey, PR | 6 |
| Cacioppo, F | 1 |
| Schwameis, M | 1 |
| Schuetz, N | 1 |
| Oppenauer, J | 1 |
| Schnaubelt, S | 1 |
| Simon, A | 1 |
| Lutnik, M | 1 |
| Gupta, S | 1 |
| Roth, D | 1 |
| Herkner, H | 1 |
| Spiel, AO | 1 |
| Laggner, AN | 1 |
| Domanovits, H | 1 |
| Niederdoeckl, J | 1 |
| Ma, C | 1 |
| Lin, JL | 1 |
| Bai, R | 1 |
| Sun, Y | 1 |
| Drago, F | 2 |
| Tamborrino, PP | 1 |
| Blomström-Lundqvist, C | 1 |
| Bigot, G | 1 |
| Kędziora, P | 1 |
| Stasiak, A | 1 |
| Curtis, AB | 1 |
| Zeitler, EP | 1 |
| Malik, A | 1 |
| Bogard, A | 1 |
| Bhattacharyya, N | 1 |
| Sethi, NJ | 1 |
| Nielsen, EE | 1 |
| Safi, S | 1 |
| Feinberg, J | 1 |
| Gluud, C | 1 |
| Jakobsen, JC | 1 |
| Osman, W | 1 |
| Hanson, M | 1 |
| Baranchuk, A | 1 |
| Atreya, AR | 1 |
| Priya, A | 1 |
| Pack, QR | 1 |
| Pekow, PS | 1 |
| Stefan, M | 1 |
| Lagu, T | 1 |
| Lotfi, AS | 1 |
| Lindenauer, PK | 1 |
| Löbe, S | 1 |
| Salmáš, J | 1 |
| John, S | 1 |
| Kornej, J | 1 |
| Husser, D | 1 |
| Hindricks, G | 1 |
| Bollmann, A | 1 |
| Chaubey, VK | 1 |
| Chhabra, L | 1 |
| Kapila, A | 1 |
| Teme, T | 1 |
| Goldberger, JJ | 1 |
| Kim, MH | 2 |
| Lin, J | 2 |
| Jhaveri, M | 1 |
| Koren, A | 1 |
| Hamilton, A | 1 |
| Clark, D | 1 |
| Gray, A | 1 |
| Cragg, A | 1 |
| Grubb, N | 1 |
| Guerra, F | 1 |
| Crijns, HJ | 6 |
| Aliot, EM | 2 |
| Radzik, D | 2 |
| Roy, D | 2 |
| Connolly, S | 1 |
| Capucci, A | 2 |
| Crochelet, AS | 1 |
| Jacquemart, C | 1 |
| Massin, M | 1 |
| Lin, PH | 1 |
| Wu, HH | 1 |
| Tsai, HD | 1 |
| Hsieh, CT | 1 |
| Montero-Tinnirello, J | 1 |
| Magaldi, M | 1 |
| Fontanals, J | 1 |
| Masgoret, P | 1 |
| Bravo, JC | 1 |
| Piga, M | 1 |
| Cocco, MC | 1 |
| Serra, A | 1 |
| Boi, F | 1 |
| Loy, M | 1 |
| Mariotti, S | 1 |
| Coletta, AP | 1 |
| Cleland, JG | 2 |
| Cullington, D | 1 |
| Clark, AL | 1 |
| Haas, NA | 1 |
| Wegendt, C | 1 |
| Schäffler, R | 1 |
| Kirchner, G | 1 |
| Welisch, E | 1 |
| Kind, K | 1 |
| Blanz, U | 1 |
| Kececioglu, D | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Kim, DD | 1 |
| Young, S | 1 |
| Cutfield, R | 1 |
| Bodalski, R | 1 |
| Maryniak, A | 1 |
| Walczak, F | 1 |
| Szumowski, L | 1 |
| Jedynak, Z | 1 |
| Bronzetti, G | 2 |
| D'Angelo, C | 2 |
| Mariucci, E | 1 |
| Picchio, FM | 2 |
| Boriani, G | 2 |
| Angelini, A | 1 |
| Zimetbaum, PJ | 1 |
| Patel, C | 1 |
| Yan, GX | 1 |
| Connolly, SJ | 4 |
| Torp-Pedersen, C | 4 |
| van Eickels, M | 2 |
| Gaudin, C | 2 |
| Page, RL | 2 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Bariş, S | 1 |
| Güzeltaş, A | 1 |
| Seymen, G | 1 |
| Ozyilmaz, I | 1 |
| Güler Eroğlu, A | 1 |
| Oztunç, F | 1 |
| Christiansen, CB | 1 |
| Køber, L | 1 |
| Dilber, E | 1 |
| Mutlu, M | 1 |
| Dilber, B | 1 |
| Aslan, Y | 1 |
| Gedik, Y | 1 |
| Celiker, A | 1 |
| Lewalter, T | 1 |
| Cooper, JA | 1 |
| Duray, GZ | 1 |
| Schmitt, J | 1 |
| Johnston, SS | 1 |
| Patel, PP | 1 |
| Schulman, KL | 1 |
| Abid, L | 1 |
| Trabelsi, I | 1 |
| Maazoun, Y | 1 |
| Krichène, S | 1 |
| Laroussi, L | 1 |
| Hammami, R | 1 |
| Abid, D | 1 |
| Sahnoun, M | 1 |
| Mallek, S | 1 |
| Triki, F | 1 |
| Hentati, M | 1 |
| Kammoun, S | 1 |
| Wolbrette, D | 1 |
| Gonzalez, M | 1 |
| Samii, S | 2 |
| Banchs, J | 1 |
| Penny-Peterson, E | 2 |
| Naccarelli, G | 1 |
| Hughes, PJ | 1 |
| Freeman, MK | 1 |
| Cohenour, FV | 1 |
| Price, EM | 1 |
| Maund, E | 1 |
| McKenna, C | 1 |
| Sarowar, M | 1 |
| Fox, D | 1 |
| Stevenson, M | 1 |
| Pepper, C | 1 |
| Palmer, S | 1 |
| Woolacott, N | 1 |
| Wolbrette, DL | 2 |
| Banchs, JE | 1 |
| Gonzalez, MD | 1 |
| Isiadinso, I | 1 |
| Meshkov, AB | 1 |
| Gaughan, J | 1 |
| Sandhu, P | 1 |
| Lim, S | 1 |
| Cordova, F | 1 |
| Criner, G | 1 |
| Gao, S | 1 |
| Juhaeri, J | 1 |
| Schiappacasse, HA | 1 |
| Koren, AT | 1 |
| Dai, WS | 1 |
| Hamid, AK | 1 |
| Richards, AM | 1 |
| Crozier, IG | 1 |
| Lainchbury, JG | 1 |
| Melton, I | 1 |
| Bridgman, PG | 1 |
| Palmer, SC | 1 |
| Frampton, CM | 1 |
| Nicholls, MG | 1 |
| Camm, AJ | 1 |
| Halperin, JL | 1 |
| Joyner, C | 1 |
| Alings, M | 1 |
| Amerena, J | 1 |
| Avezum, Á | 1 |
| Blomström, P | 1 |
| Borggrefe, M | 1 |
| Budaj, A | 1 |
| Chen, SA | 4 |
| Ching, CK | 1 |
| Commerford, P | 1 |
| Dans, A | 1 |
| Davy, JM | 1 |
| Delacrétaz, E | 1 |
| Di Pasquale, G | 1 |
| Diaz, R | 1 |
| Dorian, P | 1 |
| Flaker, G | 1 |
| Golitsyn, S | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Granger, CB | 1 |
| Heidbüchel, H | 1 |
| Kautzner, J | 2 |
| Kim, JS | 1 |
| Lanas, F | 1 |
| Lewis, BS | 1 |
| Merino, JL | 1 |
| Morillo, C | 1 |
| Murin, J | 1 |
| Narasimhan, C | 1 |
| Paolasso, E | 1 |
| Parkhomenko, A | 1 |
| Peters, NS | 1 |
| Sim, KH | 1 |
| Stiles, MK | 1 |
| Tanomsup, S | 1 |
| Toivonen, L | 1 |
| Tomcsányi, J | 1 |
| Tse, HF | 1 |
| Vardas, P | 1 |
| Vinereanu, D | 1 |
| Xavier, D | 1 |
| Zhu, JR | 1 |
| Baret-Cormel, L | 1 |
| Weinling, E | 1 |
| Staiger, C | 1 |
| Yusuf, S | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Rotondi, F | 1 |
| Lanzillo, T | 1 |
| Manganelli, F | 1 |
| Lanni, F | 1 |
| Alfano, F | 1 |
| Stanco, G | 1 |
| Rosato, G | 1 |
| Christoph, M | 1 |
| Guenther, M | 1 |
| Wunderlich, C | 1 |
| Blecher, GE | 1 |
| Stiell, IG | 1 |
| Rowe, BH | 1 |
| Lang, E | 1 |
| Brison, RJ | 1 |
| Perry, JJ | 1 |
| Clement, CM | 1 |
| Borgundvaag, B | 1 |
| Langhan, T | 1 |
| Magee, K | 1 |
| Stenstrom, R | 1 |
| Birnie, D | 1 |
| Wells, GA | 1 |
| Biondi, B | 1 |
| Hennersdorf, MG | 1 |
| Perings, SM | 1 |
| Zühlke, C | 1 |
| Heidland, UE | 1 |
| Perings, C | 1 |
| Heintzen, MP | 1 |
| Strauer, BE | 1 |
| Khand, AU | 1 |
| Deedwania, PC | 1 |
| Aouate, P | 1 |
| Elbaz, N | 1 |
| Klug, D | 2 |
| Lacotte, J | 1 |
| Raguin, D | 1 |
| Frank, R | 1 |
| Lelouche, D | 1 |
| Dubois-Randé, JL | 1 |
| Tonet, J | 1 |
| Fontaine, G | 1 |
| Ouarda, F | 1 |
| M'Saad, H | 1 |
| Chaker, L | 1 |
| Hakim, K | 1 |
| Abid, F | 1 |
| Jalil, E | 1 |
| Mensour, B | 1 |
| Vinet, A | 1 |
| Kus, T | 1 |
| Hauser, TH | 2 |
| Pinto, DS | 2 |
| Josephson, ME | 3 |
| Zimetbaum, P | 3 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 3 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Vereckei, A | 1 |
| Zipes, DP | 1 |
| Besch, H | 1 |
| Tada, H | 1 |
| Ozaydin, M | 1 |
| Chugh, A | 2 |
| Scharf, C | 2 |
| Oral, H | 2 |
| Pelosi, F | 2 |
| Knight, BP | 1 |
| Strickberger, SA | 1 |
| Morady, F | 2 |
| Trappe, HJ | 1 |
| Brandts, B | 1 |
| Weismueller, P | 1 |
| Tai, CT | 3 |
| Lin, YK | 1 |
| Lan, FC | 1 |
| Chen, HY | 1 |
| Ding, YA | 2 |
| Chang, MS | 4 |
| Strasburger, JF | 1 |
| Cuneo, BF | 1 |
| Michon, MM | 1 |
| Gotteiner, NL | 1 |
| Deal, BJ | 1 |
| McGregor, SN | 1 |
| Oudijk, MA | 1 |
| Meijboom, EJ | 1 |
| Feinkind, L | 1 |
| Hussey, M | 1 |
| Parilla, BV | 1 |
| Cihá, R | 1 |
| Peichl, P | 1 |
| Bertaglia, E | 1 |
| Bonso, A | 1 |
| Zoppo, F | 1 |
| Proclemer, A | 1 |
| Verlato, R | 1 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Themistoclakis, S | 1 |
| Raviele, A | 1 |
| Pascotto, P | 1 |
| Fatemi, M | 1 |
| Mansourati, J | 1 |
| Rosu, R | 1 |
| Blanc, JJ | 1 |
| G Akar, J | 1 |
| J Wilber, D | 1 |
| Maury, P | 2 |
| Zimmermann, M | 1 |
| Lad, V | 1 |
| Ventura, M | 1 |
| Elvas, L | 1 |
| Providência, L | 1 |
| Perdrix-Andujar, L | 1 |
| Paziaud, O | 1 |
| Ricard, G | 1 |
| Diebold, B | 1 |
| Le Heuzey, JY | 1 |
| Sedrakyan, A | 1 |
| Treasure, T | 1 |
| Browne, J | 1 |
| Krumholz, H | 1 |
| Sharpin, C | 1 |
| van der Meulen, J | 1 |
| Dilaveris, P | 1 |
| Synetos, A | 1 |
| Giannopoulos, G | 1 |
| Gialafos, E | 1 |
| Stefanadis, C | 1 |
| Aasbo, JD | 1 |
| Lawrence, AT | 1 |
| Krishnan, K | 1 |
| Trohman, RG | 2 |
| Fragakis, N | 1 |
| Papadopoulos, N | 1 |
| Papanastasiou, S | 1 |
| Kozirakis, M | 1 |
| Maligkos, G | 1 |
| Tsaritsaniotis, E | 1 |
| Katsaris, G | 1 |
| Schuetz, P | 1 |
| Eriksson, U | 1 |
| Christ-Crain, M | 1 |
| Zulewski, H | 1 |
| Miller, B | 1 |
| Kathofer, S | 1 |
| Thomas, D | 1 |
| Karle, CA | 1 |
| Pappone, C | 1 |
| Good, E | 1 |
| Bogun, F | 1 |
| Bates, ER | 1 |
| Lehmann, MH | 1 |
| Vicedomini, G | 1 |
| Augello, G | 1 |
| Agricola, E | 1 |
| Sala, S | 1 |
| Santinelli, V | 1 |
| Zareba, KM | 1 |
| Helm, C | 1 |
| Kum, LC | 1 |
| Chan, WW | 1 |
| Hui, HH | 1 |
| Wong, GW | 1 |
| Ho, SS | 1 |
| Sanderson, JE | 1 |
| Yu, CM | 1 |
| Fung, JW | 1 |
| Da Costa, A | 1 |
| Thévenin, J | 1 |
| Roche, F | 1 |
| Romeyer-Bouchard, C | 1 |
| Abdellaoui, L | 1 |
| Messier, M | 1 |
| Denis, L | 1 |
| Faure, E | 1 |
| Gonthier, R | 1 |
| Kruszynski, G | 1 |
| Pages, JM | 1 |
| Bonijoly, S | 1 |
| Lamaison, D | 1 |
| Defaye, P | 1 |
| Barthélemy, JC | 1 |
| Gouttard, T | 1 |
| Isaaz, K | 1 |
| Kafkas, NV | 1 |
| Patsilinakos, SP | 1 |
| Mertzanos, GA | 1 |
| Papageorgiou, KI | 1 |
| Chaveles, JI | 1 |
| Dagadaki, OK | 1 |
| Kelesidis, KM | 1 |
| Alcalde, RV | 1 |
| Guaragna, JC | 1 |
| Bodanese, LC | 1 |
| Castro, I | 1 |
| Sussenbach, E | 1 |
| Noer, R | 1 |
| Goldani, MA | 1 |
| Feier, F | 1 |
| Petracco, JB | 1 |
| Iskandar, SB | 1 |
| Byrd, RP | 1 |
| Xu, HK | 1 |
| Zhang, YF | 1 |
| Dale, KM | 1 |
| White, CM | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Foley, P | 1 |
| Kalra, P | 1 |
| Andrews, N | 1 |
| Singh, BN | 3 |
| Ezekowitz, MD | 1 |
| Knirsch, W | 1 |
| Kretschmar, O | 1 |
| Vogel, M | 1 |
| Uhlemann, F | 1 |
| Bauersfeld, U | 1 |
| Daccarett, M | 1 |
| Segerson, NM | 1 |
| Weiss, JP | 1 |
| Day, JD | 1 |
| Kawabata, M | 1 |
| Hirao, K | 1 |
| Higuchi, K | 1 |
| Sasaki, T | 1 |
| Furukawa, T | 1 |
| Okada, H | 1 |
| Hachiya, H | 1 |
| Isobe, M | 1 |
| Peters, RW | 1 |
| Coumel, P | 3 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Leclercq, JF | 2 |
| Assayag, P | 1 |
| Verza, M | 1 |
| Cacciapuoti, F | 1 |
| Tedesco, MA | 1 |
| Gentile, S | 1 |
| Di Costanzo, A | 1 |
| Caprioli, V | 1 |
| Varricchio, M | 1 |
| Garson, A | 1 |
| Gillette, PC | 1 |
| McVey, P | 1 |
| Hesslein, PS | 1 |
| Porter, CJ | 1 |
| Angell, LK | 1 |
| Kaldis, LC | 1 |
| Hittner, HM | 1 |
| Dick, M | 1 |
| Campbell, RM | 1 |
| Graboys, TB | 1 |
| Podrid, PJ | 1 |
| Lown, B | 1 |
| Gronda, M | 1 |
| Occhetta, E | 1 |
| Magnani, A | 1 |
| Rognoni, G | 1 |
| D'Aurelio, M | 1 |
| Prando, MD | 1 |
| Rossi, P | 1 |
| Faniel, R | 1 |
| Schoenfeld, P | 1 |
| Nademanee, K | 2 |
| Hendrickson, JA | 1 |
| Reed, AW | 1 |
| Melmed, S | 1 |
| Hershman, J | 1 |
| Critelli, G | 1 |
| Gallagher, JJ | 1 |
| Perticone, F | 1 |
| Monda, V | 1 |
| Coltorti, F | 1 |
| Condorelli, M | 1 |
| Suzzi, G | 1 |
| Candelpergher, G | 1 |
| Buchberger, R | 1 |
| Simoncello, P | 1 |
| Cernetti, C | 1 |
| Ricevuti, A | 1 |
| Bianchi, C | 1 |
| Bonifazi, C | 1 |
| Coppetti, S | 1 |
| Ferrari, O | 1 |
| Rinaldo, R | 1 |
| Rizzi, M | 1 |
| Tavecchi, L | 1 |
| Zampaglione, G | 1 |
| Ziletti, G | 1 |
| Distante, S | 1 |
| Piras, L | 1 |
| Frau, G | 2 |
| Terrosu, P | 2 |
| Sannia, L | 2 |
| Dore, L | 2 |
| Carta, G | 1 |
| Ibba, GV | 2 |
| Rowland, E | 2 |
| Krikler, DM | 2 |
| Hou, ZY | 1 |
| Chen, CY | 1 |
| Tu, MS | 1 |
| Lin, SL | 1 |
| Chiang, HT | 1 |
| Woosley, RL | 1 |
| Chun, SH | 1 |
| Sager, PT | 1 |
| Stevenson, WG | 1 |
| Middlekauff, HR | 1 |
| Andrivet, P | 2 |
| Boubakri, E | 1 |
| Dove, PJ | 1 |
| Mach, V | 2 |
| Vu Ngoc, C | 1 |
| Pisapia, A | 1 |
| Bine-Scheck, F | 1 |
| Schenowitz, A | 1 |
| Domerego, JJ | 1 |
| Maraud, L | 1 |
| Canler, A | 1 |
| Labban, N | 1 |
| Viart, R | 1 |
| Aubry, P | 1 |
| Beruben, E | 1 |
| Cochrane, AD | 1 |
| Siddins, M | 1 |
| Rosenfeldt, FL | 1 |
| Salamonsen, R | 1 |
| McConaghy, L | 1 |
| Marasco, S | 1 |
| Davis, BB | 1 |
| Till, JA | 1 |
| Baxendall, M | 1 |
| Benetar, A | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 1 |
| Lüderitz, B | 1 |
| Flack, NJ | 1 |
| Zosmer, N | 1 |
| Bennett, PR | 1 |
| Vaughan, J | 1 |
| Fisk, NM | 1 |
| Ahsan, A | 1 |
| Aldridge, R | 1 |
| Bowes, R | 1 |
| Chapman, MJ | 1 |
| Moran, JL | 1 |
| O'Fathartaigh, MS | 1 |
| Peisach, AR | 1 |
| Cunningham, DN | 1 |
| Gnoc, CV | 1 |
| Di Biasi, P | 1 |
| Scrofani, R | 1 |
| Paje, A | 1 |
| Cappiello, E | 1 |
| Mangini, A | 1 |
| Santoli, C | 1 |
| van 't Hof, AW | 1 |
| Mosterd, A | 1 |
| Suttorp, MJ | 1 |
| Vaksmann, G | 1 |
| Lacroix, D | 1 |
| Kumar, A | 1 |
| Maragnès, P | 1 |
| Iselin, M | 1 |
| David, N | 1 |
| Foucault, JP | 1 |
| Kounis, NG | 1 |
| Frangides, C | 1 |
| Papadaki, PJ | 1 |
| Zavras, GM | 1 |
| Goudevenos, J | 1 |
| Larbuisson, R | 1 |
| Venneman, I | 1 |
| Stiels, B | 1 |
| Matiouchine, GV | 1 |
| Shulman, VA | 1 |
| Balog, AI | 2 |
| Bezruk, AP | 1 |
| Golovenkin, SE | 2 |
| Tieleman, RG | 1 |
| Gosselink, AT | 1 |
| van Gelder, IC | 2 |
| van den Berg, MP | 1 |
| de Kam, PJ | 1 |
| van Gilst, WH | 2 |
| Lie, KI | 2 |
| Heisel, A | 1 |
| Jung, J | 1 |
| Fries, R | 1 |
| Stopp, M | 1 |
| Sen, S | 1 |
| Schieffer, H | 1 |
| Ozbek, C | 1 |
| Le Cosquer, P | 1 |
| Guerin-Robardey, AM | 1 |
| Ossart, M | 1 |
| Basta, M | 1 |
| Klein, GJ | 1 |
| Yee, R | 1 |
| Krahn, A | 1 |
| Lee, J | 1 |
| Huang, DT | 1 |
| Monahan, KM | 1 |
| Papageorgiou, P | 1 |
| Epstein, LM | 1 |
| Feng, AN | 2 |
| Yu, WC | 2 |
| Chen, YJ | 2 |
| Mazza, A | 1 |
| Garibaldi, S | 1 |
| Mafrici, A | 1 |
| Santilli, A | 1 |
| Ragonese, P | 1 |
| Matiushin, GV | 1 |
| Shul'man, VA | 1 |
| Smirnova, OV | 1 |
| Iervasi, G | 1 |
| Clerico, A | 1 |
| Bonini, R | 1 |
| Nannipieri, M | 1 |
| Manfredi, C | 1 |
| Sabatino, L | 1 |
| Biagini, A | 1 |
| Donato, L | 1 |
| Vuille, C | 1 |
| Metzger, J | 1 |
| Veragut, B | 1 |
| Schoenenberger, I | 1 |
| Elamly, A | 1 |
| Chevrolet, JC | 1 |
| Carrel, T | 1 |
| Meyer, B | 1 |
| Candinas, R | 1 |
| Turina, M | 1 |
| Schmid, ER | 1 |
| Chiang, CE | 1 |
| Lee, SH | 1 |
| Geelen, P | 1 |
| Brugada, P | 1 |
| Reithmann, C | 1 |
| Hoffmann, E | 1 |
| Spitzlberger, G | 1 |
| Dorwarth, U | 1 |
| Gerth, A | 1 |
| Remp, T | 1 |
| Steinbeck, G | 1 |
| Dell'Orfano, JT | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Joseph, AP | 1 |
| Ward, MR | 1 |
| Nielsen, KD | 1 |
| Møller, S | 1 |
| Bianconi, L | 1 |
| Castro, A | 1 |
| Dinelli, M | 1 |
| Alboni, P | 1 |
| Pappalardo, A | 1 |
| Richiardi, E | 1 |
| Santini, M | 1 |
| Glatter, K | 1 |
| Yang, Y | 1 |
| Chatterjee, K | 1 |
| Modin, G | 1 |
| Cheng, J | 1 |
| Kayser, S | 1 |
| Scheinman, MM | 1 |
| Wirth, KJ | 1 |
| Knobloch, K | 1 |
| Delle Karth, G | 1 |
| Geppert, A | 1 |
| Neunteufl, T | 1 |
| Priglinger, U | 1 |
| Haumer, M | 1 |
| Gschwandtner, M | 1 |
| Siostrzonek, P | 1 |
| Heinz, G | 1 |
| Sloan, SB | 1 |
| Weitz, HH | 1 |
| Doggrell, SA | 1 |
| Wurdeman, RL | 1 |
| Mooss, AN | 1 |
| Mohiuddin, SM | 1 |
| Lenz, TL | 1 |
| Shiga, T | 1 |
| Wakaumi, M | 1 |
| Imai, T | 1 |
| Suzuki, T | 1 |
| Hosaka, F | 1 |
| Yamada, Y | 1 |
| Matsuda, N | 1 |
| Shoda, M | 1 |
| Sugiura, R | 1 |
| Hagiwara, N | 1 |
| Kasanuki, H | 1 |
| Attuel, P | 1 |
| Lavallée, J | 1 |
| Flammang, D | 1 |
| Slama, R | 1 |
| Donaldson, RM | 1 |
| Brochier, M | 1 |
| Fauchier, JP | 1 |
| Demoulin, JC | 1 |
| Legrand, V | 1 |
| Greco, R | 1 |
| Musto, B | 1 |
| De Martino, U | 1 |
| Marsico, F | 1 |
| Ferrero, C | 1 |
| Gavaliatsis, IP | 1 |
| Kouvousis, NM | 1 |
| Rallidis, LS | 1 |
| Pirros, JM | 1 |
| Dionisopoulou, CT | 1 |
| Kremastinos, DT | 1 |
| Tsitouris, GK | 1 |
| Hijazi, ZM | 1 |
| Rosenfeld, LE | 1 |
| Copel, JA | 1 |
| Kleinman, CS | 1 |
| Vietti-Ramus, G | 1 |
| Veglio, F | 2 |
| Marchisio, U | 2 |
| Burzio, P | 2 |
| Latini, R | 1 |
| Vietti Ramus, G | 1 |
| Bonino, ML | 1 |
| Bigo, P | 1 |
| Leopaldi, D | 1 |
| Ricco, G | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Potapenko, PI | 1 |
| Kapustin, AI | 1 |
| Strukov, VV | 1 |
| McAlister, HF | 1 |
| Luke, RA | 1 |
| Whitlock, RM | 1 |
| Smith, WM | 2 |
| Kushakovskiĭ, MS | 1 |
| Rebrova, GA | 1 |
| Mostow, ND | 1 |
| Vrobel, TR | 1 |
| Noon, D | 1 |
| Rakita, L | 1 |
| Kay, GN | 1 |
| Haines, DE | 1 |
| Lerman, BB | 1 |
| DiMarco, JP | 1 |
| Luceri, RM | 1 |
| Castellanos, A | 1 |
| Thurer, RJ | 1 |
| Myerburg, RJ | 1 |
| Bischoff, KH | 1 |
| Assmann, I | 1 |
| Dittrich, P | 1 |
| Meissner, C | 1 |
| Schwela, H | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Bayés de Luna, A | 1 |
| Oter, MC | 1 |
| Guindo, J | 1 |
| Bushe, C | 1 |
| McKenna, WJ | 1 |
| Martin, A | 1 |
| Benbow, LJ | 1 |
| Leach, C | 1 |
| Bailey, RJ | 1 |
| Friehling, TD | 1 |
| Marinchak, RA | 1 |
| Sulpizi, AM | 1 |
| Stohler, JL | 1 |
| Leroy, G | 1 |
| Haiat, R | 1 |
| Barthelemy, M | 1 |
| Lionnet, F | 1 |
| Brown, MA | 1 |
| Lubbe, WF | 1 |
| Norris, RM | 1 |
| Bucknall, CA | 1 |
| Keeton, BR | 1 |
| Curry, PV | 1 |
| Tynan, MJ | 1 |
| Sutherland, GR | 1 |
| Holt, DW | 1 |
| Clarke, B | 1 |
| Ward, DE | 1 |
| Honey, M | 1 |
| Storelli, A | 1 |
| Andriulo, C | 1 |
| Chisena, A | 1 |
| De Giorgi, M | 1 |
| De Giorgio, NA | 1 |
| Gallone, V | 1 |
| Guadalupi, M | 1 |
| Lupis, O | 1 |
| Nadovezza, S | 1 |
| Tarentini, A | 1 |
| Strasberg, B | 1 |
| Arditti, A | 1 |
| Sclarovsky, S | 1 |
| Lewin, RF | 1 |
| Buimovici, B | 1 |
| Agmon, J | 1 |
| Petelenz, T | 1 |
| Jastrzebska, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785] | Phase 3 | 4,628 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors[NCT01151137] | Phase 3 | 3,236 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to The study was stopped because of safety concerns) | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Tailored Treatment of Permanent Atrial Fibrillation - TTOP-AF[NCT00514735] | Phase 3 | 210 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI[NCT01182376] | Phase 3 | 33 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prevention of Atrial Fibrillation by the Prescription of Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter[NCT00736294] | Phase 3 | 198 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Difficulty to include patients) | ||
| EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)[NCT00259428] | Phase 3 | 615 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)[NCT00259376] | Phase 3 | 629 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrill[NCT00489736] | Phase 3 | 504 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| "Population Pharmacokinetics and Pharmacodynamics of Amiodarone in Children: PK-AMIO"[NCT03842020] | 57 participants (Actual) | Interventional | 2019-02-13 | Completed | |||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)[NCT04190186] | 90 participants (Anticipated) | Interventional | 2020-06-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 63 |
| Placebo | 90 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 65 |
| Placebo | 94 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 116 |
| Placebo | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 675 |
| Placebo | 859 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 734 |
| Placebo | 917 |
Deaths were classified according to the primary cause of death. (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any death | - Cardiovascular death | --- Cardiac arrhythmic death | |
| Dronedarone | 25 | 21 | 13 |
| Placebo | 13 | 10 | 4 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01151137)
Timeframe: from first study drug intake up to 10 days after the last study drug intake
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any AE | - Any serious AE | - Any AE leading to death | - Any AE leading to treatment discontinuation | - Any AE leading to hospitalization | |
| Dronedarone | 797 | 113 | 4 | 212 | 95 |
| Placebo | 600 | 77 | 0 | 80 | 71 |
(NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| MI or unstable angina pectoris | - MI | Stroke | - Ischemic stroke | Systemic arterial embolism | Episode of heart failure | - Hospitalization due to heart failure | Unplanned hospitalization for cardiovascular cause | |
| Dronedarone | 15 | 3 | 23 | 18 | 1 | 115 | 43 | 113 |
| Placebo | 8 | 2 | 10 | 9 | 0 | 55 | 24 | 59 |
"First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.~Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.~Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |
|---|---|---|
| First co-primary endpoint | Second co-primary endpoint | |
| Dronedarone | 43 | 127 |
| Placebo | 19 | 67 |
"Time to cardiovascular death was defined as the time from randomization to the death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.003 | 0.005 | 0.008 | 0.022 | 0.026 | 0.026 |
| Placebo | 0.001 | 0.003 | 0.004 | 0.004 | 0.027 | 0.027 |
"Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.009 | 0.013 | 0.021 | 0.042 | 0.045 | 0.045 |
| Placebo | 0.002 | 0.003 | 0.007 | 0.013 | 0.038 | 0.038 |
"Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.020 | 0.034 | 0.069 | 0.110 | 0.137 | 0.137 |
| Placebo | 0.005 | 0.014 | 0.033 | 0.059 | 0.099 | 0.099 |
"A treatment success/failure up to the conclusion of the procedure for each subject in Ablation Management. A subject was considered successfully treated if the following were true:~Medtronic ablation catheters were used to achieve procedure success.~All accessible pulmonary veins were isolated.~At least 50% reduction of complex fractionated atrial electrograms mapped and ablated with Medtronic ablation catheters.~Sinus rhythm was achieved upon leaving the electrophysiology lab (±cardioversion)." (NCT00514735)
Timeframe: Procedure conclusion
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 92.8 |
The primary endpoint for acute safety was a success/failure variable calculated for each subject in Ablation Management at the 7 day post-procedure time point. Any subject with at least one adverse event adjudicated by the Data Safety Monitoring Board as both serious and either probably or definitely procedure and/or device-related occurring within 7 days of the ablation procedure was considered an acute safety failure, regardless of whether the event occurred following the index or retreatment ablation procedure. (NCT00514735)
Timeframe: 7 days
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 12.3 |
"The chronic efficacy endpoint was a treatment success/failure measure for each subject computed at 6 months. Treatment success included:~A 90% reduction in clinically significant atrial fibrillation from baseline to the 6 month time point based on a Holter recording. Clinically significant atrial fibrillation was defined as sustained atrial fibrillation lasting more than 10 minutes.~The subject was off all antiarrhythmic drugs at 6 months (Ablation Management arm only)~The Investigator judged all procedures to be acutely successful (Ablation Management arm only)." (NCT00514735)
Timeframe: 6 months
| Intervention | percentage of participants with success (Number) |
|---|---|
| Ablation Management | 56 |
| Medical Management | 26 |
The primary endpoint for chronic safety was a success/failure variable calculated for each subject at 6 months. Any subject that had at least one adverse event that met designated seriousness and relatedness criteria for the particular treatment group as adjudicated by the Data Safety Monitoring Board was considered a chronic safety failure. Adverse events in Ablation Management that were acute (≤7 days) were not included in the chronic safety primary endpoint. Given the disparity in the length of time at risk between treatment arms,the Chronic Safety endpoint was not statistically powered. (NCT00514735)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Ablation Management | 9 |
| Medical Management | 3 |
The SF-36 questionnaire was administered to subjects at baseline, 1, 3 and 6 month visits. The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based Physical Component Score and Mental Component Score. The possible range for Physical Component Score and Mental Component Score is 0 to 100. The higher score, the better quality of life. (NCT00514735)
Timeframe: 6 months
| Intervention | Scores on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Component Score at Baseline | Physical Component Score at 1 Month | Physical Component Score at 3 Months | Physical Component Score at 6 Months | Mental Component Score at Baseline | Mental Component Score at 1 Month | Mental Component Score at 3 Months | Mental Component Score at 6 Months | |
| Ablation Management | 42.54 | 45.61 | 48.30 | 49.12 | 47.19 | 51.53 | 53.42 | 53.45 |
| Medical Management | 42.26 | 43.05 | 43.99 | 44.98 | 47.99 | 48.96 | 48.97 | 50.06 |
The severity of subject's atrial fibrillation related symptoms on a scale from 1 (no symptoms) to 5 (most severe). The symptoms included palpitations, fatigue, shortness of breath, lightheadedness or dizziness, and lack of energy during exertion or exercise. The scores were tabulated at the 1, 3 and 6 month follow-up visits. Scores could range from 5 to 25, indicating a spectrum of subject status from asymptomatic to severely symptomatic. (NCT00514735)
Timeframe: 6 months
| Intervention | AF Symptom Severity Score (Mean) | |||
|---|---|---|---|---|
| Measurement at Baseline | Measurement at 1 Month | Measurement at 3 Months | Measurement at 6 Months | |
| Ablation Management | 12.38 | 8.95 | 7.56 | 7.58 |
| Medical Management | 12.72 | 9.90 | 10.03 | 9.84 |
Left atrial diameter (LAD), as measured by transthoracic echocardiogram (TTE) looking at the longitudinal long axis at baseline and at the 6 month follow-up visit in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | centimeters (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 4.5 | 4.4 |
| Medical Management | 4.6 | 4.6 |
Left ventricular ejection fraction (LVEF), as measured by transthoracic echocardiogram at baseline and 6 months in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | percent (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 54.7 | 58.3 |
| Medical Management | 54.9 | 57.0 |
The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment. (NCT01182376)
Timeframe: baseline, 1 year
| Intervention | percentage of fibrosis (Mean) |
|---|---|
| Placebo | 24.6 |
| Multaq® (Dronedarone) | 16.8 |
"The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 83 |
| Amiodarone 600mg/200mg od | 107 |
"The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 61 |
| Amiodarone 600mg/200mg od | 99 |
"The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 184 |
| Amiodarone 600mg/200mg od | 141 |
29 reviews available for amiodarone and Atrial Flutter
| Article | Year |
|---|---|
Atrial Flutter in Pediatric Patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Child; Child, Preschool; D | 2022 |
Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Bias; Calcium Channel Blockers; Comorbidity; | 2018 |
The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Half-Lif | 2014 |
Dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Ion Ch | 2009 |
Efficacy and safety of dronedarone: a review of randomized trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Fa | 2010 |
[Supraventricular tachycardia in infants].
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Decision Support | 2011 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Contraindications; Dronedar | 2010 |
Dronedarone: an alternative to amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; D | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2010 |
A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Controlled Clinical Trials | 2010 |
Mechanisms in endocrinology: Heart failure and thyroid dysfunction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; | 2012 |
Prevention of and medical therapy for atrial arrhythmias in heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2002 |
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: evidence from randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Human | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availab | 2007 |
Successful treatment of atrial flutter with amiodarone in a premature neonate. Case report and literature review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Humans; Infant, Newborn; Infant, Premature; Tach | 2007 |
[Cardioversion of atrial flutter and fibrillation with amiodarone in high doses].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Female; Humans; Male; Mid | 1982 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Calcium Channel Blockers; Digoxin; El | 1997 |
[Severe flecainide acetate poisoning. Apropos of a case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Biological Availability; Calcium Gluconate | 1999 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Supraventricular tachycardia: implications for the intensivist.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiogra | 2000 |
Postoperative arrhythmias and conduction disorders.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; | 2001 |
Amiodarone -- waxed and waned and waxed again.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Pres | 2001 |
Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Artery Bypas | 2002 |
34 trials available for amiodarone and Atrial Flutter
| Article | Year |
|---|---|
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Humans; Kidney; R | 2022 |
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans | 2022 |
Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Treatm | 2022 |
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Hospitalizatio | 2023 |
Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Humans | 2022 |
The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
[Efficacy of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Results of the EURIDIS and ADONIS].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Dronedaron | 2008 |
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cause of Death; Comb | 2011 |
Post-ATHENA and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2003 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Flutter; Catheter Ablation; Female; Follow-Up Studies; F | 2006 |
Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Respon | 2007 |
High dose of amiodarone in a short-term period reduces the incidence of postoperative atrial fibrillation and atrial flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Female | 2006 |
[Comparison between therapeutic effects of acupuncture and intravenous injection of amiodarone in the treatment of paroxymal atrial fibrillation and atrial flutter].
Topics: Acupuncture Therapy; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2007 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; | 2007 |
Amiodarone treatment of critical arrhythmias in children and young adults.
Topics: Adolescent; Adult; Amiodarone; Atrial Flutter; Benzofurans; Child; Child, Preschool; Clinical Trials | 1984 |
Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study.
Topics: Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Digo | 1995 |
A clinical study of amiodarone as a single oral dose in patients with recent-onset atrial tachyarrhythmia.
Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Female; Follow-Up Studi | 1994 |
[Value of cibenzoline in the preventive treatment of recurrent atrial arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atr | 1994 |
A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Digoxin; Female; | 1994 |
Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; Dos | 1995 |
The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Fe | 1996 |
Isolated neonatal atrial flutter: clinical features, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Electric Countershoc | 1998 |
Effect of antiarrhythmic therapy with intravenous loading dose of amiodarone: evidence for an altered response in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fib | 1998 |
A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Topics: Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; | 2000 |
Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2000 |
Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atria | 2000 |
Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; APACHE; Atrial Fibrillation; Atrial | 2001 |
Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Card | 1990 |
Interatrial conduction block with retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmias: influence of preventive antiarrhythmic treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; | 1989 |
Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report).
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Disopyramide; Female; Humans; Ma | 1986 |
136 other studies available for amiodarone and Atrial Flutter
| Article | Year |
|---|---|
[The Chinese expert recommendations on the clinical use of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; China; Dronedarone; Humans | 2021 |
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.
Topics: Adonis; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; | 2022 |
Cardioversion of Post-Ablation Atrial Tachyarrhythmia with Ibutilide and Amiodarone: A Registry-Based Cohort Study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cohort Studies; Electric Co | 2022 |
Atrial Flutter-Unique Arrhythmia in Neonatal Population, Presentation of 3 Cases.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Electrocardiography; Femal | 2020 |
Pseudo-Ventricular Tachycardia, Pseudo-Atrial Fibrillation, and Pseudo-Atrial Flutter in a Patient With Parkinson Disease: Two's Company, Three's a Crowd.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Diagnosis, Differential; El | 2019 |
Use and Outcomes Associated With Perioperative Amiodarone in Cardiac Surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cohort Studies; Coron | 2019 |
Usefulness of dronedarone in patients with atrial arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Dose-Response Relationship, Drug; Dronedar | 2013 |
Ataxia: a diagnostic perplexity and management dilemma.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Flutter; Diagnosis, Differential; Female; F | 2013 |
Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Proc | 2013 |
Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atr | 2014 |
The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2015 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2014 |
[Repeated electrical cardioversions and amiodarone for recurrent neonatal atrial flutter].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Electric Countershock; Humans; Infant, Newborn; | 2015 |
Successful treatment of atrial flutter by repeated intraperitoneal and intra-amniotic injections of amiodarone in a fetus with hydrops.
Topics: Adult; Amiodarone; Amnion; Anti-Arrhythmia Agents; Atrial Flutter; Female; Humans; Hydrops Fetalis; | 2016 |
Sinusal reversion of supraventricular tachyarrhythmias after propofol administration. A case series.
Topics: Adenosine; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Fema | 2017 |
Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiotonic Agents; Clinica | 2008 |
ECMO for cardiac rescue in a neonate with accidental amiodarone overdose.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Drug Overdose; Extracorporeal Membrane Oxygenati | 2008 |
A survey of thyroid function test abnormalities in patients presenting with atrial fibrillation and flutter to a New Zealand district hospital.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2008 |
[Glass of water or ablation? - episodes of malignant atrial tachyarrhythmias during swimming in a lake in a woman with overt Wolff-Parkinson-White syndrome and benign palpitations for several decades of life].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter | 2008 |
Incompatibility between intravenous amiodarone and heparin in an infant.
Topics: Amiodarone; Atrial Flutter; Drug Interactions; Female; Heparin; Humans; Infant; Infusions, Intraveno | 2010 |
Resolution of atrial thrombosis with heparin in a newborn with atrial flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Electrocardiography; Fibrinolytic Agent | 2009 |
Dronedarone for atrial fibrillation--an odyssey.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinic | 2009 |
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrill | 2009 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Intractable atrial flutter presented with severe bradycardia in an infant.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Bradycardia; Cataract; Electric Countershock; El | 2009 |
Intravenous amiodarone used alone or in combination with digoxin for life-threatening supraventricular tachyarrhythmia in neonates and small infants.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Drug Evaluation; Drug Therap | 2010 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electroc | 2010 |
Dronedarone is superior to placebo the case for optimism.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electroc | 2010 |
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Dis | 2010 |
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Co | 2010 |
Atrial arrhythmias after lung and heart-lung transplant: effects on short-term mortality and the influence of amiodarone.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2011 |
Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Co | 2011 |
Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Chi-S | 2011 |
Atypical response of class IC atrial flutter to adenosine.
Topics: Adenosine; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Female; Hu | 2011 |
Amiodarone induced interatrial electrical dissociation mimics restored sinus rhythm in patient with persistent left atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Atrioventricular Block; Diagnosis, Differe | 2012 |
Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2012 |
Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Critical Care; Electr | 2002 |
[Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial | 2002 |
[Atrial flutter in neonates and infants: diagnosis and treatment].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Echocardiography; Electric Countershock; Electro | 2002 |
Excitable gap composition in the presence of antiarrhythmic drugs in common human atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Female; Heart Co | 2003 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs.
Topics: Amiodarone; Animals; Atrial Flutter; Chronic Disease; Dogs; Drug Therapy, Combination; Electrocardio | 2003 |
Effects of isoproterenol and amiodarone on the double potential interval after ablation of the cavotricuspid isthmus.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Flutter; Drug Synerg | 2003 |
Conduction properties of the crista terminalis in patients with atrial flutter due to amiodarone therapy for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrophysiology; Fe | 2003 |
Amiodarone therapy for drug-refractory fetal tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Electrocardiography; Female; Fetal Dise | 2004 |
Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter.
Topics: Age Factors; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atri | 2004 |
Double potentials as a criterion for cavotricuspid isthmus block?
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Flutter; Drug Synerg | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Value of entrainment mapping in determining the isthmus-dependent nature of atrial flutter in the presence of amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Body Surface Potential Mapping; Cardiac Pa | 2004 |
Amiodarone and the excitable gap: where do we go from here?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrophysiologic Techniques | 2004 |
Effect of chronic amiodarone therapy on excitable gap during typical human atrial flutter.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Arti | 2004 |
Recurrence of atrial fibrillation and flutter after atrial compartment operation: modified atrial incisions and role of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cryosurgery; Heart Atria; H | 2005 |
Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Follow-Up Studies; Humans; Re | 2004 |
[1/1 nodo-ventricular conduction atrial flutter with amiodarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Atrioventricular Node; Heart Conduction Sy | 2005 |
Conversion of recent-onset atrial fibrillation or flutter with amiodarone after ibutilide has failed: a rapid, efficient, and safe algorithm.
Topics: Aged; Algorithms; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atr | 2005 |
Summaries for patients. Potential benefits of amiodarone for patients undergoing open-heart surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
[Amiodarone-induced thyrotoxicosis: a diagnostic and therapeutic challenge].
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Atrial Flutter; Carbima | 2005 |
Dronedarone: a new antiarrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availab | 2006 |
Country cardiograms case 30. Atrial flutter with aberrancy, and 3:2 A-V conduction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Female; Humans | 2006 |
Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction.
Topics: Alanine Transaminase; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Fl | 2006 |
Drug modified arrhythmia: what's your diagnosis?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flu | 2006 |
Amiodarone--avoid the danger of torsade de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Female; Humans; Tachyca | 2008 |
Maintaining sinus rhythm--making treatment better than the disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Failure; | 2007 |
Dual tachycardia in the setting of amiodarone-induced hyperthyroidism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; | 2007 |
Clinical and electrophysiological characteristics of patients having atrial flutter with 1:1 atrioventricular conduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Case | 2008 |
[Treatment of supraventricular tachycardia].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter | 1981 |
The use of amiodarone in children.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Bundle-Branch Bl | 1983 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
[Temporary electric stimulation in the treatment of atrial flutter in the aged subject].
Topics: Aged; Amiodarone; Atrial Flutter; Electric Stimulation Therapy; Female; Humans; Male | 1984 |
Advances in the management of cardiac arrhythmias in children.
Topics: Adolescent; Adult; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pa | 1984 |
Efficacy of amiodarone for refractory supraventricular tachyarrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1983 |
Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Dose-Response Relationshi | 1983 |
Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy.
Topics: Adult; Aged; Amiodarone; Atrial Flutter; Benzofurans; Electrocardiography; Heart Ventricles; Humans; | 1982 |
[Closed chest interruption of A-V conduction in the treatment of refractory supraventricular tachyarrhythmias. A clinical contribution].
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Digitalis Glycosides; E | 1982 |
[High-frequency electrostimulation of the atrium in therapy of atrial flutter in patients pre-treated with amiodarone].
Topics: Adult; Aged; Amiodarone; Atrial Flutter; Benzofurans; Electric Countershock; Female; Humans; Male; M | 1982 |
[Experience with intravenous amiodarone in hyperkinetic supraventricular arrhythmias].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Fem | 1981 |
[Treatment of atrial arrythmias with amiodarone. Short-term and long-term results].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Female; Humans; Male; Mid | 1981 |
[Pharmacologic cardioversion with intravenous amiodarone].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Humans; Injections, Intra | 1981 |
Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Ele | 1980 |
Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Evaluation Studies as Topic; | 1995 |
Acceleration of the ventricular response to atrial flutter by amiodarone in an infant with Wolff-Parkinson-White syndrome.
Topics: Amiodarone; Atrial Flutter; Heart; Humans; Infant, Newborn; Male; Wolff-Parkinson-White Syndrome | 1993 |
Amiodarone given by three routes to terminate fetal atrial flutter associated with severe hydrops.
Topics: Adult; Amiodarone; Atrial Flutter; Drug Administration Routes; Edema; Female; Humans | 1993 |
1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide.
Topics: Aged; Amiodarone; Atrial Flutter; Atrioventricular Node; Digoxin; Drug Therapy, Combination; Electro | 1993 |
Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Female; Heart Rate; Humans; I | 1993 |
A clinical study of intravenous cibenzoline in selected patients with recent-onset atrial tachyarrhythmia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Humans; Imidazoles; | 1993 |
Amiodarone for prevention of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Humans | 1996 |
Radiofrequency ablation of the His bundle for malignant atrial flutter after Mustard procedure for transposition of the great arteries.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Bundle of His; Catheter Ablation; Hu | 1996 |
Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Critic | 1996 |
[Late supraventricular arrhythmia complicating Fontan or cavopulmonary type procedures. Apropos of 7 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Premature Complexes; Cardiac Pacing, Arti | 1996 |
Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Dose-Response Relationship, Drug; Humans; | 1996 |
Combined transesophageal left atrial pacing and antiarrhythmic therapy in the treatment of atrial flutter.
Topics: Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Fun | 1996 |
Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Echocardiography; Ele | 1997 |
Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1997 |
[Modern therapy of tachycardiac heart arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Flutter; Humans; | 1995 |
[Amiodarone-induced thyrotoxicosis cured by thyroidectomy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiomyopathy, Hypertrophic; Humans; Male; Midd | 1996 |
Amiodarone as treatment for atrial tachycardias after surgery.
Topics: Administration, Oral; Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cathete | 1997 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 1998 |
Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Functi | 1998 |
[Combined use of left atrial transesophageal pacing and cordarone in atrial flutter].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Combined Modality Th | 1998 |
Intravenous amiodarone versus propafenone for atrial fibrillation and flutter after cardiac surgery: a note of caution.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures | 1996 |
Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; El | 1999 |
Hybrid therapy for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Humans | 2000 |
Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; F | 2000 |
Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Therapy, Combina | 2001 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, L | 2001 |
Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; A | 2002 |
[The atrial arrhythmia syndrome of vagal origin].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Drug Resistance | 1978 |
The treatment of supraventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhyt | 1979 |
["Torsades de pointe" and reentry induced by anti-arrhythmia agents].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutte | 1978 |
[The place of amiodarone in 1979 in the therapeutic arsenal of a cardiac intensive care unit].
Topics: Amiodarone; Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; | 1979 |
[Treatment of atrial flutter and fibrillation with amiodarone and digitalis].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Digoxin; Female; Humans; | 1977 |
[Treatment of auricular flutter and fibrillation with amiodarone and digitalis].
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Digitalis Glycosides; Humans | 1977 |
Recurrent atrial flutter in apical hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Flutter; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Echocardiograp | 1992 |
Amiodarone therapy of intractable atrial flutter in a premature hydropic neonate.
Topics: Adult; Amiodarone; Atrial Flutter; Electrocardiography; Female; Humans; Hydrops Fetalis; Hypothyroid | 1992 |
Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Dose-Response Re | 1992 |
[The acute treatment of supraventricular tachycardia with endovenous amiodarone].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Response Relat | 1991 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
[The use of transesophageal electrical stimulation of the left atrium combined with the intravenous administration of kordaron for managing paroxysms of atrial flutter].
Topics: Adult; Aged; Amiodarone; Atrial Flutter; Cardiac Pacing, Artificial; Combined Modality Therapy; Esop | 1991 |
[Experience with long-term outpatient use of cordarone in the prevention of paroxysms of atrial fibrillation (flutter)].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Humans; Middle Aged; Time Factors | 1990 |
Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone.
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Ev | 1990 |
Invited letter concerning: amiodarone and quinidine for postoperative atrial arrhythmias.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Humans; Quinidine | 1990 |
Repetitive supraventricular tachycardia: clinical manifestations and response to therapy with amiodarone.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Dose-Response Relationshi | 1986 |
Noninvasive conversion of atrial flutter using a multiprogrammable DDD pulse generator.
Topics: Amiodarone; Atrial Flutter; Combined Modality Therapy; Electrocardiography; Heart Block; Heart Rate; | 1986 |
[Deglutition-induced supraventricular tachycardias].
Topics: Amiodarone; Atrial Flutter; Bundle of His; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; | 1989 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
The treatment of atrial flutter with high-dose amiodarone.
Topics: Aged; Amiodarone; Atrial Flutter; Electrocardiography; Humans; Infusions, Intravenous; Male | 1989 |
Amiodarone for the conversion of established atrial fibrillation and flutter.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Humans | 1986 |
Safety and efficacy of amiodarone. The low-dose perspective.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; E | 1988 |
Torsade de pointes during loading with amiodarone.
Topics: Administration, Oral; Amiodarone; Atrial Flutter; Cardiac Pacing, Artificial; Dose-Response Relation | 1987 |
Amiodarone-induced torsades de pointes.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Benzofurans; Dru | 1986 |
Intravenous and oral amiodarone for arrhythmias in children.
Topics: Administration, Oral; Adolescent; Amiodarone; Arrhythmias, Cardiac; Atrial Flutter; Child; Child, Pr | 1986 |
Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Combined Modality Therapy; Exer | 1985 |
[Intravenous amiodarone in the therapy of paroxysmal supraventricular tachycardias].
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Female; Human | 1985 |
Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Benzofurans; El | 1985 |
[Effectiveness of electric cardioversion after premedication with amiodarone].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Electric Countershock; Female; | 1985 |